Trials / Unknown
UnknownNCT04156243
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD19 CARvac in Patients With Relapsed and/or Refractory B Cell Malignancies
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- iCell Gene Therapeutics · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
Detailed description
CD19 CARvac is a chimeric antigen receptor immunotherapy treatment designed to treat
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19 CARvac T cells | CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy. |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2020-02-28
- Completion
- 2020-02-28
- First posted
- 2019-11-07
- Last updated
- 2019-11-12
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04156243. Inclusion in this directory is not an endorsement.